Recursion Pharmaceuticals Stock News

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET Company Participants Chris Gibson - Co-Founder & Chief Executive Officer Lina Nilsson - Senior Vice President & Head of Platform Ben Taylor - Chief Financial Officer Conference Call Participants Chris Gibson Welcome everybody to Recursion's Earnings Call. I'm Chris Gibson, Co-Founder and...

SALT LAKE CITY, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its fourth quarter and fiscal year ended December 31, 2024.

Salt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call...

Recursion Pharmaceuticals' NASDAQ: RXRX stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken by artificial intelligence (AI) chip giant NVIDIA NASDAQ: NVDA. A recent SEC filing showed NVIDIA reshuffling its AI investment portfolio, and while it trimmed its holdings in several AI ventures, it notably maintained its stak...

The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones

The artificial intelligence (AI) revolution is reshaping the global economy at an unprecedented pace, with innovations emerging across every sector from healthcare to transportation. As companies race to integrate AI capabilities into products and services, investors are keenly searching for opportunities to capitalize on this technological transformation.

Shares of Recursion Pharmaceuticals (RXRX 16.12%) had soared by 15.8% as of 12:06 p.m. ET on Friday.

Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to keep their doors open during a pre-revenue period while they develop drug treatments and other medical products, but the process can be slow and, for those on the outside, opaque. Then, if all goes according to plan, these firms may see success in the form of promising data,...